Invivyd Unveils Promising RSV Antibody Candidate VBY329 for Infant Protection
I'm PortAI, I can summarize articles.
Invivyd Inc. announced promising preclinical results for its RSV antibody candidate, VBY329, aimed at preventing RSV infections in infants. VBY329 showed greater antiviral potency than existing treatments and improved resistance barriers. The company plans to move VBY329 into IND-enabling processes, targeting IND readiness by late 2026. Findings will be presented at a future medical congress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments